RETATRUTIDE·MINNESOTA·LAST CHECKED 1 NOV 2026
Is Retatrutide legal in Minnesota?
CAVEATS APPLY
We found no Minnesota statute, board rule or enforcement action that names Retatrutide, so federal law applies. Not as a drug. Retatrutide has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. Pharmacies cannot compound it.
CATEGORY · INVESTIGATIONAL
Full status breakdown
FEDERAL · STATE · SPORT-BODYFederal status
FDA approval
DEA scheduling
not scheduled
503A compounding
FDA interim category: Not in any FDA category
503A Bulks List: not on list
Not eligible. Retatrutide has no FDA approval, no USP monograph and is not on the 503A Bulks List; FDA warning letters state it cannot be lawfully compounded. Ohio's Board of Pharmacy names it as a research-use-only drug its inspectors find in clinics.
FDA Warning Letters
- Dec 10, 2024 — Summit Research Peptides (cited: retatrutide, tirzepatide) · LETTER ↗
- Dec 10, 2024 — Xcel Research LLC (cited: retatrutide, cagrilintide, mazdutide) · LETTER ↗
- Sep 9, 2025 — GLP-1 Solution (cited: retatrutide) · LETTER ↗
- Mar 31, 2026 — Gram Peptides (cited: retatrutide, tirzepatide) · LETTER ↗
- Mar 31, 2026 — Prime Sciences (cited: retatrutide) · LETTER ↗
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: FDA has consistently rejected 'research use only' labeling as a safe harbor when site evidence (dosing instructions, vials/syringes, comparisons to weight-loss drugs) shows human-use intent. Multiple Warning Letters cite this exact pattern for retatrutide.
Personal possession: Personal possession of unapproved investigational peptides sits in a regulatory gray zone. FDA enforcement focus has been on vendor-side marketing and sale, not buyer-side possession, but no formal safe harbor exists.
Minnesota — state-specific
Sport-body status
WADA 2026
prohibited · class S0 · in and out of competition
Not named, and GLP-1 agonists as a class are not on the 2026 List. Retatrutide falls under S0 because no government has approved it. WADA's 2027 List, in force from 1 Jan 2027, now names 'peptides' among the S0 examples; the status does not change.
USADA
banned
NCAA
unknown
What we couldn’t verify
Also known as
7 ALIASESRetatrutide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
LY3437943GLP-3triple-GGGG triple agonistGLP-1/GIP/glucagon triple agonistRETAR-10mg
Related
FOLLOW-ONS- Are peptides legal in the US? — all 44 compounds in one table
- Retatrutide research guide — mechanism, published research, public lab records
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
Retatrutide: US status, sources and what changed
Other states with a rule that names Retatrutide: Ohio, California. Everywhere else, federal law applies.